Skip to main content
SpringerLink
Log in

Die wichtigsten Studienergebnisse der primären Radiochemotherapie von Kopf-Hals-Tumoren

Highlights vom ASCO-Meeting 2012

The most important results on primary chemoradiation for head and neck squamous cell carcinoma

Highlights from the 2012 ASCO meeting

  • Leitthema
  • Published:
HNO Aims and scope Submit manuscript

Zusammenfassung

Die primäre Radiochemotherapie wird in konkomitanter und sequenzieller Form in der Therapie von Kopf-Hals-Tumoren zunehmend verwendet. Beim jährlichen Meeting der American Society of Clinical Oncology 2012 wurden zahlreiche Studien zu diesem Thema vorgestellt. Eine Auswahl dieser Studien wird in diesem Artikel vorgestellt. Unter anderem werden Ergebnisse mehrerer Phase-III-Studien – auch über den lang erwarteten Vergleich von Induktionschemotherapie und konkomitanter Radiochemotherapie – präsentiert.

Abstract

Primary concomitant and sequential chemoradiation is a commonly used therapeutic strategy for head and neck squamous cell carcinoma. At the annual meeting of the 2012 American Society of Clinical Oncology numerous trial results were presented. A selection of the most important trials will be summarized in this article. This year, several important results from phase III trials—including the long awaited comparison of sequential and concomitant chemoradiation—were demonstrated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ang K, Zhang Q, Wheeler RH et al (2010) A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): impact of radiation and cisplatin intensity on outcome. ASCO Meeting Abstracts 28:5507

    Google Scholar 

  2. Ang KK, Zhang QE, Rosenthal DI et al (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). ASCO Meeting Abstracts 29:5500

    Google Scholar 

  3. Austin M, Schmidt R, Parvathaneni U et al (2012) Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: a phase II randomized trial. ASCO Meeting Abstracts 30:5515

    Google Scholar 

  4. Budach V, Cho C-H, Sedlmaier B et al (2012) Five years‘ results of the German ARO 04–01 trial of concurrent 72 Gy hyperfractionated accelerated radiation therapy (HART) plus once weekly cisplatinum/5-FU versus mitomycin C/5-FU in stage IV head and neck cancer. ASCO Meeting Abstracts 30:5512

    Google Scholar 

  5. Budach V, Stuschke M, Budach W et al (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95–06 Prospective Randomized Trial. J Clin Oncol 23:1125–1135

    Article  PubMed  CAS  Google Scholar 

  6. Cohen Eew, Karrison T, Kocherginsky M et al (2012) DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). ASCO Meeting Abstracts 30:5500

    Google Scholar 

  7. Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098

    Article  PubMed  CAS  Google Scholar 

  8. Ghi MG, Paccagnella A, Ferrari D et al (2012) Cetuximab/radiotherapy (CET+ RT) versus concomitant chemoradiotherapy (cCHT+ RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Preliminary results on toxicity of a randomized, 2 × 2 factorial, phase II-III study (NCT01086826). ASCO Meeting Abstracts 30:5513

    Google Scholar 

  9. Gillison Ml, Zhang Q, Jordan R et al (2012) Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 30:2102–2111

    Article  PubMed  CAS  Google Scholar 

  10. Giralt J, Fortin A, Mesia R et al (2012) A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). ASCO Meeting Abstracts 30:5502

    Google Scholar 

  11. Haddad RI, Rabinowits G, Tishler RB et al (2012) The PARADIGM trial: a phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). ASCO Meeting Abstracts 30:5501

    Google Scholar 

  12. Lorch JH, Goloubeva O, Haddad RI et al (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12:153–159

    Article  PubMed  CAS  Google Scholar 

  13. Martins R, Parvathaneni U, Sharma AK et al (2012) Randomized phase II trial of cisplatin and radiotherapy with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). ASCO Meeting Abstracts 30:5503

    Google Scholar 

  14. Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715

    Article  PubMed  CAS  Google Scholar 

  15. Stoehlmacher-Williams J, Villanueva C, Foa P et al (2012) Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (−) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the global phase III SPECTRUM trial. ASCO Meeting Abstracts 30:5504

    Google Scholar 

  16. Vermorken JB, Remenar E, Van Herpen C et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704

    Article  PubMed  CAS  Google Scholar 

  17. Wuthrick EJ, Zhang Q, Machtay M et al (2012) The influence of institutional head and neck cancer (HNC) clinical trial accrual on overall survival (OS): an analysis of RTOG 0129. ASCO Meeting Abstracts 30:5530

    Google Scholar 

Download references

Interessenkonflikt

S. Laban erhielt Studienunterstützung in Form von Sorafenib Reinsubstanz von Bayer Healthcare.

R. Knecht übt beratende Tätigkeiten ohne Honorar für Merck Serono, Sanofi Aventis, Boehringer Ingelheim und Bayer Healthcare Leverkusen aus.

Die übrigen Autoren geben an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Kopf-Hals-Tumorzentrum des Universitären Cancer Center Hamburg, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland

    S. Laban, V. Zielinski, C.-J. Busch, A. Münscher & R. Knecht

  2. Medizinische Klinik und Poliklinik für Hämatologie und Onkologie, Kopf-Hals-Tumorzentrum des Universitären Cancer Center Hamburg, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

    P. Schafhausen

  3. Ambulanzzentrum Bereich Strahlentherapie, Kopf-Hals-Tumorzentrum des Universitären Cancer Center Hamburg, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

    S. Tribius

Authors
  1. S. Laban
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Zielinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C.-J. Busch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Münscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Schafhausen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Tribius
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Knecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Laban.

Additional information

S. Laban und V. Zielinski teilen sich die Erstautorenschaft.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laban, S., Zielinski, V., Busch, CJ. et al. Die wichtigsten Studienergebnisse der primären Radiochemotherapie von Kopf-Hals-Tumoren. HNO 60, 962–967 (2012). https://doi.org/10.1007/s00106-012-2595-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00106-012-2595-x

Schlüsselwörter

Keywords

Search

Navigation